Loading...
Loading...
IKNA| Name | Value |
|---|---|
| Revenues | 1.2M |
| Cost of Revenue | 0.2M |
| Gross Profit | 0.9M |
| Operating Expense | 20.7M |
| Operating I/L | -19.5M |
| Other Income/Expense | 2.2M |
| Interest Income | 2.2M |
| Pretax | -17.3M |
| Income Tax Expense | -0.2M |
| Net Income/Loss | -17.3M |
Ikena Oncology, Inc. is a targeted oncology company specializing in developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company's lead product candidate, IK-930, is an oral small molecule inhibitor targeting the Hippo signaling pathway. Additionally, Ikena Oncology is developing small molecule inhibitors against ERK5 in the RAS signaling pathway, an oral inhibitor of aryl hydrocarbon receptor, and an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer.
